TULSA, Okla. – Central States Research in South Tulsa is participating in the AHEAD study which aims to help prevent Alzheimer’s disease.
Dr Sarah Land, owner of Central States Research, LLC, says the investigational drug called BAN 2-4-0-1 attacks amyloid plaques that build up in the brain and eventually lead to Alzheimer’s disease.
âPart of how we hope these drugs can work is to either prevent these plaques from forming or reduce development over time,â said Dr. Land.
The study is looking for participants aged 55 to 65 who have a first-degree relative with Alzheimer’s disease, or aged 65 to 80 who do not need to have a first-degree relative with Alzheimer’s disease. Alzheimer’s disease. Participants cannot already be diagnosed with Alzheimer’s disease, but must have a buildup of amyloid plaque in their brains, which is determined by tests performed during the study.
Rita Nye, who is participating in the study, lost her father Paul to Alzheimer’s disease when he was 84.
“I hope yes this will help me and yes I will notâ¦ if there is a cure I will be ecstatic.” Even if not, as a nurse, retired nurse, I hope I can help future generations, âNye said.
Nye says she’s already started to experience some of the symptoms of Alzheimer’s disease, things like forgetting eggs on the stove, her purse at the store, and even not being able to remember the word for something. .
âThe biggest fear is that you just aren’t who you used to be. They can kind of become just a shell of a person and I don’t want to be that and I don’t want that for my husband, âNye said.
Dr Land says the study needs more participants and more diversity in their research clinic and other participating clinics in cities across the United States and around the world.
âLatinos and African Americans are overrepresented in populations with dementia and underrepresented in research and it is so important to bring these people here,â said Dr. Land.
Central States Research is the only Oklahoma lab participating in the study.
Â© 2021 Cox Media Group